Browsing Tag
VB4-P5
2 posts
Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004?
Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside?
XORTX surges after $3M Vectus Biosystems deal adds promising anti-fibrotic kidney drug to pipeline
Find out how XORTX’s $3 million Vectus Biosystems acquisition could reshape the renal fibrosis market and accelerate its transformation into a leading kidney disease innovator.